Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Healthcare Journal Guam.
Press releases published on September 24, 2025
Cytokinetics Announces Call for Proposals for Its Eighth Annual Communications Grant Program
Program to Provide Support of Communications and Outreach for Patient Advocacy Organizations Focused on Cardiovascular Diseases Deadline for Applications is November 3rd, 2025 SOUTH SAN FRANCISCO, Calif., Sept. 24, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, …
uniQure Announces Refinancing of Existing $50 Million Debt and Securing Up to an Additional $125 Million in Non-Dilutive Funding
~ Term of current $50 million debt outstanding extended from January 2027 to October 2030 ~ ~ Additional $100 million available subject to regulatory and financial milestones ~ ~ Additional $25 million available subject to Hercules’ approval ~ ~ …
Healthcare as the World’s Most Strategic Investment: KFSHRC CEO Calls for Global Collaboration at C3 Japan Summit
TOKYO, Sept. 24, 2025 (GLOBE NEWSWIRE) -- Healthcare must be recognized as the world’s most strategic investment in security, prosperity, and resilience—not as a financial burden—declared H.E. Dr. Majid Alfayyadh, Adviser at the Saudi Royal Court and Chief …
Insight Molecular Diagnostics to Showcase Leadership in Kidney Transplant Management at Conferences in Singapore and Orlando
IMDX to host symposium on Wednesday, September 24th to discuss GraftAssureIQ™ at International Association of Therapeutic Drug Monitoring and Clinical Toxicology (IATDMCT) annual meeting Presenting on GraftAssureIQ at symposium on Thursday, October 9th at …
uniQure Announces Positive Topline Results from Pivotal Phase I/II Study of AMT-130 in Patients with Huntington’s Disease
~ Pivotal study met primary endpoint; high-dose AMT-130 demonstrated statistically significant 75% disease slowing at 36 months as measured by cUHDRS compared to a propensity score-matched external control ~ ~ High-dose AMT-130 also demonstrated …
BIO-Europe® 2025: Vienna Prepares to Welcome Global Biopharma Leaders
MUNICH, Sept. 24, 2025 (GLOBE NEWSWIRE) -- Excitement is building for the 31st annual edition of BIO-Europe, the premier partnering conference for the global biopharmaceutical industry, which will take place in Vienna, Austria, from November 3 - 5, 2025. …
LUKE Calls for National Partnerships to Help America’s Heroes Flourish
NASHVILLE, Tenn., Sept. 24, 2025 (GLOBE NEWSWIRE) -- As the American Association of Christian Counselors (AACC) World Conference in Nashville opens, LUKE Holdings, Inc. (“LUKE”), a trusted leader in healthcare staffing for the U.S. Government, is extending …
Sagimet Biosciences Announces Upcoming Panel Participation at Fierce Biotech Week
SAN MATEO, Calif., Sept. 24, 2025 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Sagimet, Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today announced its …
FibroGen Initiates Phase 2 Monotherapy Trial of FG-3246, a First-in-Class CD46 Targeting ADC, in Metastatic Castration-Resistant Prostate Cancer
FG-3246 Phase 2 dose optimization trial to enroll 75 patients with metastatic castration-resistant prostate cancer (mCRPC) in the post-androgen receptor signaling inhibitor (ASRI) and pre-chemotherapy setting FG-3180 to be evaluated in the Phase 2 trial as …
Cidara Therapeutics Announces Expanded and Accelerated Phase 3 Plan for CD388, a Non-Vaccine Preventative of Seasonal Influenza
- Update based on FDA End-of- Phase 2 meeting outcome - Phase 3 study start accelerated by six months, in time for the fall 2025 Northern Hemisphere flu season - A single Phase 3 trial of CD388, if successful, may be sufficient for BLA approval - Phase 3 …
Palvella Therapeutics Announces Expansion of QTORIN™ Rapamycin’s Development into Clinically Significant Angiokeratomas, a Rare, Chronically Debilitating Lymphatic Disease with No FDA-approved Therapies
Clinically significant angiokeratomas are characterized by lymphatic-derived skin lesions that can persistently bleed and significantly impact quality-of-life; no FDA-approved therapies exist for the estimated more than 50,000 diagnosed U.S. patients …
ITM and TerThera Sign Supply Agreement for Medical Radioisotope Terbium-161
Garching / Munich, Germany, and Breda, the Netherlands, September 24, 2025 – ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, and TerThera BV, a leading provider of GMP-grade Terbium-161, today announced a supply …
CARBIOS berichtet Finanzergebnisse für das erste Halbjahr 2025 und bestätigt seinen Plan, eine PET-Biorecyclinganlage zu bauen, mit überarbeitetem Zeitplan
CARBIOS hat seine betrieblichen Aufwendungen gesenkt und verfügt zum 30. Juni 2025 über eine starke Liquiditätsposition von 72 Millionen Euro, die dem Unternehmen eine Reichweite der liquiden Finanzmittel für einen Zeitraum von über zwölf Monaten …
CARBIOS presents its 2025 half-year results and confirms its objective to build a PET biorecycling plant, with a revised timeline.
CARBIOS has reduced its operating expenses and has a strong cash position of €72 million as of June 30, 2025, providing a cash horizon of more than 12 months The Longlaville plant construction project is now supported by: Major progress with public …
CARBIOS présente ses résultats semestriels 2025 et confirme son objectif de construction d’usine de biorecyclage du PET avec un calendrier décalé
CARBIOS a réduit ses dépenses opérationnelles et dispose d’une solide position de trésorerie de 72 millions d’euros au 30 juin 2025, lui permettant de disposer d'un horizon de trésorerie de plus de 12 mois. Le projet de construction de l'usine de …
Burning Rock's OncoGuide™ OncoScreen™ Plus CDx System Now Approved in Japan as a Companion Diagnostic for Capivasertib in Breast Cancer
TOKYO and GUANGZHOU, China, Sept. 24, 2025 (GLOBE NEWSWIRE) -- Riken Genesis Co., Ltd. (Riken Genesis) and Burning Rock Biotech Limited (NASDAQ: BNR, “Burning Rock”) today announced that the OncoGuide™ OncoScreen™ Plus CDx System based on OncoScreen™ Plus …
Correction of a Material Error Relating to the Total Number of Voting Rights and Shares Comprising the Share Capital
Correction of a Material Error Relating to the Total Number of Voting Rights and Shares Comprising the Share Capital Clarification in Response to Unfounded Accusations NANTES, France – September 24, 2025, 8:00 a.m. CET – OSE Immunotherapeutics SA (ISIN: …
Correction d’une erreur matérielle relative au nombre total de droits de vote et d’actions composant le capital
Correction d’une erreur matérielle relative au nombre total de droits de vote et d’actions composant le capital Mise au Point Face aux Accusations Infondées Nantes, le 24 septembre 2025 à 8 h 00 CET –OSE Immunotherapeutics (ISIN : FR0012127173 ; Mnémo : …
Aesthetics Ave Elevates Non-Surgical Cosmetic Treatments in Midland, TX
Offering Facial Fillers, Wrinkle Reduction, Non-Surgical Facelifts, and Morpheus 8 Skin Treatments for Natural, Youthful Results MIDLAND, Sept. 24, 2025 (GLOBE NEWSWIRE) -- Aesthetics Ave, a premier destination for advanced cosmetic and aesthetic …